9月24日，麦迪科技盘中上涨2.34%，截至13:03，报14.45元/股，成交5340.48万元，换手率1.23%，总市 值44.26亿元。 截至6月30日，麦迪科技股东户数3.63万，较上期减少24.87%；人均流通股8429股，较上期增加 33.09%。2025年1月-6月，麦迪科技实现营业收入1.35亿元，同比减少47.24%；归母净利润2832.75万 元，同比增长137.11%。 分红方面，麦迪科技A股上市后累计派现7135.67万元。近三年，累计派现0.00元。 机构持仓方面，截止2025年6月30日，麦迪科技十大流通股东中，鹏华碳中和主题混合A（016530）位 居第八大流通股东，持股219.36万股，为新进股东。 责任编辑：小浪快报 今年以来麦迪科技已经8次登上龙虎榜，最近一次登上龙虎榜为3月10日，当日龙虎榜净买入3115.92万 元；买入总计1.15亿元 ，占总成交额比8.31%；卖出总计8361.32万元 ，占总成交额比6.06%。 资料显示，苏州麦迪斯顿医疗科技股份有限公司位于江苏省苏州工业园区归家巷222号，成立日期2009 年8月14日，上市日期2016年12月8日，公司主营业务 ...

Core Viewpoint - The stock of Weining Health has shown fluctuations in recent trading sessions, with a notable increase of 2.05% on September 24, 2023, while the company faces a significant decline in revenue and profit for the first half of 2025 [1][2]. Group 1: Stock Performance - As of September 24, 2023, Weining Health's stock price reached 8.96 CNY per share, with a market capitalization of 19.836 billion CNY [1]. - The stock has increased by 25.40% year-to-date, but has seen declines of 4.38% over the last five trading days, 15.39% over the last twenty days, and 10.22% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Weining Health reported a revenue of 839 million CNY, a decrease of 31.43% year-on-year, and a net profit of -118 million CNY, representing a decline of 491.04% [2]. - The company has distributed a total of 455 million CNY in dividends since its A-share listing, with 97.226 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 19, 2023, the number of Weining Health's shareholders was 117,800, a decrease of 0.53% from the previous period, while the average number of circulating shares per person increased by 0.53% to 16,244 shares [2]. - The top three circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 1.7506 million shares, and Yifangda Growth Enterprise ETF, which decreased its holdings by 652,300 shares [3].

Core Viewpoint - Baolait's stock price has shown a year-to-date increase of 29.59%, despite recent declines in the last five and twenty trading days, indicating volatility in its performance [2]. Company Overview - Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011. The company is located in Zhuhai, Guangdong Province, and specializes in the research, production, sales, and service of medical device products [2]. - The main revenue composition of Baolait includes hemodialysis products (77.51%), monitoring devices (21.39%), and other products (1.10%) [2]. Financial Performance - For the first half of 2025, Baolait reported operating revenue of 523 million yuan, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2]. - As of June 30, 2025, Baolait has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period. The average circulating shares per person increased by 6.50% to 11,477 shares [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]. Market Activity - On September 24, Baolait's stock price rose by 2.03% to 8.54 yuan per share, with a trading volume of 21.1786 million yuan and a turnover rate of 1.19%. The total market capitalization reached 2.259 billion yuan [1]. - The net inflow of main funds was 1.2812 million yuan, with large single purchases accounting for 10.99% of the total, while sales accounted for 4.94% [1].

Company Overview - Yimikang Technology Group Co., Ltd. is located in Chengdu High-tech Zone, Sichuan Province, and was established on September 12, 2002. The company went public on August 3, 2011 [2] - The main business involves providing green solutions for the entire lifecycle of digital infrastructure, relying on data centers to cover the entire industry chain. The company offers comprehensive solutions and services through four major segments: key equipment, intelligent engineering, IoT software, and smart services [2] - The company's revenue composition is entirely from the information data sector, accounting for 100% [2] Financial Performance - For the first half of 2025, Yimikang achieved operating revenue of 737 million yuan, representing a year-on-year growth of 54.82%. The net profit attributable to the parent company was 14.92 million yuan, with a year-on-year increase of 124.13% [2] - As of June 30, the number of shareholders was 59,700, a decrease of 8.79% from the previous period. The average circulating shares per person increased by 9.59% to 6,249 shares [2] Stock Performance - On September 24, Yimikang's stock price rose by 2.02%, reaching 17.21 yuan per share, with a trading volume of 235 million yuan and a turnover rate of 3.74%. The total market capitalization is 7.581 billion yuan [1] - Year-to-date, Yimikang's stock price has increased by 34.66%. Over the past five trading days, it has decreased by 0.23%, and over the past 20 days, it has declined by 3.59%. However, over the past 60 days, the stock price has risen by 30.78% [1] - Yimikang has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on February 14, where the net buying amount was 51.656 million yuan, accounting for 11.59% of the total trading volume [1] Dividend Information - Since its A-share listing, Yimikang has distributed a total of 51.071 million yuan in dividends. However, there have been no dividend distributions in the past three years [3]

Core Viewpoint - Tonghua Dongbao's stock price has shown a modest increase of 6.12% year-to-date, with recent fluctuations indicating a slight decline over the past 20 days and a small gain over the last 60 days [1] Group 1: Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. is located in Tonghua County, Jilin Province, and was established on December 28, 1992, with its listing date on August 24, 1994 [1] - The company's main business includes hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biological engineering products (recombinant human insulin injection) [1] - The revenue composition of the company is as follows: biological products (raw materials and formulations) 90.29%, medical devices such as injection pens and blood glucose test strips 6.07%, traditional Chinese medicine and chemical drugs 2.24%, and others 1.27% [1] Group 2: Financial Performance - For the first half of 2025, Tonghua Dongbao achieved an operating income of 1.373 billion yuan, representing a year-on-year growth of 85.60%, and a net profit attributable to shareholders of 218 million yuan, reflecting a year-on-year increase of 194.48% [2] - The company has cumulatively distributed dividends of 5.509 billion yuan since its A-share listing, with 1.973 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders of Tonghua Dongbao was 86,500, a decrease of 7.02% compared to the previous period, with an average of 22,632 circulating shares per shareholder, an increase of 7.55% [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., Ltd. and Hong Kong Central Clearing Limited, with varying changes in their holdings compared to the previous period [3]

Core Viewpoint - He Eye Hospital's stock price has experienced fluctuations, with a year-to-date increase of 2.14% but a significant decline in recent trading periods, indicating potential volatility in investor sentiment [2]. Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province. The company specializes in providing ophthalmic specialty diagnosis and treatment services [2]. - The revenue composition of He Eye Hospital includes: Vision services (30.24%), Refractive surgery correction services (24.16%), Non-surgical treatments (20.02%), Cataract diagnosis and treatment services (13.68%), Vitreoretinal diagnosis and treatment services (8.09%), Other ophthalmic diagnosis and treatment services (3.20%), and Other business income (0.61%) [2]. Financial Performance - As of June 30, 2025, He Eye Hospital reported a revenue of 560 million yuan, a year-on-year decrease of 4.22%. However, the net profit attributable to shareholders was 44.32 million yuan, reflecting a significant year-on-year increase of 84.19% [2]. - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for He Eye Hospital was 10,800, an increase of 15.03% from the previous period. The average circulating shares per person decreased by 13.07% to 7,684 shares [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund held 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3].

Company Overview - Tongrentang's stock price decreased by 2.01% on September 23, trading at 11.70 CNY per share with a market capitalization of 19.793 billion CNY [1] - The company specializes in the research, production, and sales of dietary nutritional supplements, with revenue composition as follows: Others 38.02%, Capsules 27.84%, Tablets 20.38%, Powders 13.76% [1] Financial Performance - For the first half of 2025, Tongrentang reported a revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million CNY, down 17.34% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion CNY, with 2.429 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.96% to 71,200, while the average circulating shares per person increased by 5.22% to 15,869 shares [2] - Major shareholders include E Fund's ChiNext ETF, holding 24.5972 million shares, a decrease of 648,400 shares from the previous period [3]

Company Overview - Dongfulong Technology Group Co., Ltd. is located at 1509 Duhui Road, Minhang District, Shanghai, established on December 25, 1993, and listed on February 1, 2011 [1] - The company specializes in the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems [1] Financial Performance - As of June 30, 2025, Dongfulong achieved operating revenue of 2.429 billion yuan, a year-on-year increase of 6.01% [2] - The net profit attributable to shareholders was 45.92 million yuan, a year-on-year decrease of 59.71% [2] - Cumulative cash dividends since the A-share listing amount to 1.782 billion yuan, with 512 million yuan distributed over the past three years [3] Stock Performance - On September 19, Dongfulong's stock price fell by 2.06%, trading at 14.26 yuan per share, with a total market capitalization of 10.921 billion yuan [1] - Year-to-date, the stock price has increased by 8.00%, but it has decreased by 0.42% over the last five trading days and by 7.34% over the last 20 days [1] - The stock's trading volume on September 19 was 63.97 million yuan, with a turnover rate of 0.79% [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 32,100, a rise of 2.35% from the previous period [2] - The average circulating shares per person decreased by 2.30% to 17,526 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 7.3336 million shares, a decrease of 2.1354 million shares from the previous period [3]

Group 1 - The stock price of Huashu Media fell by 2.10% on September 18, closing at 7.94 CNY per share, with a trading volume of 1.30 billion CNY and a market capitalization of 14.712 billion CNY [1] - Year-to-date, Huashu Media's stock price has increased by 13.11%, but it has decreased by 3.29% over the last five trading days and 4.34% over the last twenty days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on February 13, where it recorded a net buy of -35.2305 million CNY [1] Group 2 - Huashu Media, established on June 30, 1994, and listed on September 6, 2000, is based in Hangzhou, Zhejiang Province, and its main business includes cable television network services, new media, broadband networks, and smart city services [2] - The revenue composition of Huashu Media includes: 30.25% from integrated projects for group clients, 19.46% from internet television, 15.57% from broadband and data communication, and 11.61% from digital television, among others [2] - As of June 30, 2025, Huashu Media reported a revenue of 4.435 billion CNY, a year-on-year increase of 2.07%, and a net profit attributable to shareholders of 254 million CNY, a year-on-year increase of 4.63% [2] Group 3 - Huashu Media has distributed a total of 3.603 billion CNY in dividends since its A-share listing, with 1.149 billion CNY distributed in the last three years [3] - As of June 30, 2025, the number of shareholders of Huashu Media was 47,100, a decrease of 13.14% from the previous period [3]

Core Viewpoint - Meinian Health's stock price has shown fluctuations, with a year-to-date increase of 12.52% but a recent decline of 2.65% over the last five trading days, indicating volatility in investor sentiment [2]. Financial Performance - For the first half of 2025, Meinian Health reported a revenue of 4.109 billion yuan, a year-on-year decrease of 2.28%, and a net profit attributable to shareholders of -221 million yuan, down 2.59% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 634 million yuan, with 127 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, Meinian Health's stock price was 5.15 yuan per share, with a market capitalization of 20.158 billion yuan. The stock experienced a net outflow of 53.52 million yuan in principal funds [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on February 19, where it recorded a net buy of -155 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 8.95% to 172,400, while the average circulating shares per person increased by 9.87% to 22,471 shares [2]. - The top ten circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 1.9034 million shares, and a new entry,招商优势企业混合A, holding 60 million shares [3].